Al-Ola A Abdallah, Director of Plasma Cell Disorder Program at the University of Kansas Medical Center, shared a post on X:
“Why I believe China is bypassing the U.S. in cellular therapy innovation (CAR-T, gene editing, etc.):
Trial Volume Explosion: China is running more clinical trials in CAR-T and cellular therapies than the U.S. — and starting them faster.
Flexible Regulations: With fewer bureaucratic hurdles, trials in China get approved quicker. Think speed over red tape.
Massive Government Investment: Cell therapy is part of China’s national strategy — they’re pouring billions into biotech under plans like ‘Made in China 2025.’
Integrated Ecosystem: Hospitals, biotech firms, and academia collaborate seamlessly in China. In the U.S., it’s often siloed.
Lower R and D Costs: Research is cheaper in China. This means more experimentation, more innovation, less fear of failure.
Western-Trained Talent Coming Home: PhDs and MDs trained in the U.S. are returning to China — bringing elite knowledge and building world-class labs.
Broader Trial Inclusion: China includes sicker or more diverse patients early on, generating real-world data the FDA might delay or reject.
Global IP and Licensing Deals: Chinese firms are filing patents worldwide and partnering with top biotech companies — becoming serious global players.
Bottom line: China is moving faster, cheaper, and more aggressively in cell therapy. The U.S. still leads in discovery — but China may win in execution. Watch this space.”
More posts featuring Al-Ola A Abdallah.